GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nautilus Biotechnology Inc (NAS:NAUT) » Definitions » EV-to-FCF

Nautilus Biotechnology (Nautilus Biotechnology) EV-to-FCF : -3.03 (As of Jun. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Nautilus Biotechnology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nautilus Biotechnology's Enterprise Value is $175.44 Mil. Nautilus Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-57.85 Mil. Therefore, Nautilus Biotechnology's EV-to-FCF for today is -3.03.

The historical rank and industry rank for Nautilus Biotechnology's EV-to-FCF or its related term are showing as below:

NAUT' s EV-to-FCF Range Over the Past 10 Years
Min: -7.56   Med: 0   Max: 0
Current: -3.03

NAUT's EV-to-FCF is ranked worse than
100% of 380 companies
in the Biotechnology industry
Industry Median: 8.375 vs NAUT: -3.03

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-06), Nautilus Biotechnology's stock price is $2.60. Nautilus Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.550. Therefore, Nautilus Biotechnology's PE Ratio for today is At Loss.


Nautilus Biotechnology EV-to-FCF Historical Data

The historical data trend for Nautilus Biotechnology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nautilus Biotechnology EV-to-FCF Chart

Nautilus Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- -7.91 -1.47 -4.34

Nautilus Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.45 -7.37 -4.90 -4.34 -3.81

Competitive Comparison of Nautilus Biotechnology's EV-to-FCF

For the Biotechnology subindustry, Nautilus Biotechnology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nautilus Biotechnology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nautilus Biotechnology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Nautilus Biotechnology's EV-to-FCF falls into.



Nautilus Biotechnology EV-to-FCF Calculation

Nautilus Biotechnology's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=175.439/-57.85
=-3.03

Nautilus Biotechnology's current Enterprise Value is $175.44 Mil.
Nautilus Biotechnology's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-57.85 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nautilus Biotechnology  (NAS:NAUT) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Nautilus Biotechnology's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.60/-0.550
=At Loss

Nautilus Biotechnology's share price for today is $2.60.
Nautilus Biotechnology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.550.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Nautilus Biotechnology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Nautilus Biotechnology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Nautilus Biotechnology (Nautilus Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
2701 Eastlake Avenue East, Seattle, WA, USA, 98102
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.
Executives
Michael Seth Altman director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Subramanian Sankar officer: Senior VP, Product Development C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Gwen E Weld officer: Chief People Officer C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Anna Mowry officer: CFO and Treasurer C/O NAUTILUS BIOTECHNOLOGY, INC., 201 INDUSTRIAL RD. #310, SAN CARLOS CA 94070
Matthew B. Murphy officer: General Counsel C/O NAUTILUS BIOTECHNOLOGY, INC., 425 PONTIUS AVE N, STE 202, SEATTLE WA 98109
Sujal M Patel director, 10 percent owner, officer: CEO, President, and Secretary C/O ISILON SYSTEMS, INC., 3101 WESTERN AVENUE, SEATTLE WA 98121
Mary E. Godwin officer: Senior VP, Operations 3101 WESTERN AVENUE, SEATTLE WA 98121
Karen Akinsanya director SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Joseph Edelman 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Advisors Llc director 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Matthew L. Posard director 11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Matthew S Mcilwain director 1000 SECOND AVENUE, SUITE 3700, SEATTLE WA 98104
Benjamin A Horowitz 10 percent owner 2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Marc L Andreessen 10 percent owner C/O ARNOLD & PORTER LLP, 3 EMBARCADERO CENTER 7TH FLOOR, SAN FRANCISCO CA 94111